Transferrin Receptor 1 Overexpression Drives Proliferation and Ferroptosis Sensitivity in Glioblastoma: A Potential Therapeutic Vulnerability
Neuropathology · 2026-04 · 46 (2)
DOI: 10.1111/neup.70056 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropathology, online erschienen am 04.04.2026. Verfasst von Minakshi M Behera und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology & Lab Medicine, All India Institute of Medical Science, Bhubaneswar, India. Hauptthemen laut MEDLINE: Receptors, Transferrin, Glioblastoma, Brain Neoplasms, Cell Proliferation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
Glioblastoma (GBM) is an aggressive CNS malignancy with extensive tumor growth and invasion. Highly proliferating cells require an increased intracellular iron concentration to maintain cell metabolism. We assessed the expression of transferrin receptor 1 (TFR1), the principal iron transporter, in GBM and ascertained its clinicopathological significance, implication in pathobiology, and therapeutic potential. Ninety‐four cases of adult‐type hemispheric GBM were included, along with 60 cases of IDH‐mutant astrocytic and oligodendroglial tumors (grade 2–4) for comparison. The protein and mRNA expression were assessed by immunohistochemistry and qRT‐PCR, respectively. We used U87MG and LN229 cell lines for in vitro analysis. TFR1 expression was significantly higher in GBM than in other IDH‐mutant/lower‐grade diffuse gliomas at mRNA and protein level. The non‐tumor brain was negative on immunohistochemistry, and strong immunoreactivity was present only in GBM, indicating its diagnostic significance. SiRNA‐mediated knockdown of TFR1 was associated with reduced cell survival, proliferation, migration, invasion, and increased apoptosis in vitro. Ferroptosis induction by RSL3/FIN56 led to increased TFR1 expression and ROS generation. The pro‐ferroptotic effect of these drugs could be reversed by TFR1 knockdown. Hence, TFR1 appears to be crucially implicated in the cell survival and proliferation and ferroptosis sensitivity of malignant cells. Temozolomide in combination with siRNA‐mediated gene silencing showed a significantly higher antitumor effect than the drug or silencing alone. This may be one of the important therapeutic vulnerabilities of GBM. High TFR1 expression was associated with shorter overall survival in all gliomas together but not in GBM separately.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology & Lab Medicine, All India Institute of Medical Science, Bhubaneswar, India.
- Department of Physiology, All India Institute of Medical Science, Bhubaneswar, India.
- Department of Neurosurgery, All India Institute of Medical Science, Bhubaneswar, India.
ORCID-Profile: Minakshi M Behera, Suvendu Purkait, Amit Ghosh, Mukund N Sable, Rabi Narayan Sahu, Gaurav Chhabra
Förderung
- Indian Council of Medical Research
Zitieren
APA
Behera, M. M., Purkait, S., Ghosh, A., Sable, M. N., Sahu, R. N., & Chhabra, G. (2026). Transferrin Receptor 1 Overexpression Drives Proliferation and Ferroptosis Sensitivity in Glioblastoma: A Potential Therapeutic Vulnerability. Neuropathology, 46(2). https://doi.org/10.1111/neup.70056
Vancouver
Behera MM, Purkait S, Ghosh A, Sable MN, Sahu RN, Chhabra G. Transferrin Receptor 1 Overexpression Drives Proliferation and Ferroptosis Sensitivity in Glioblastoma: A Potential Therapeutic Vulnerability. Neuropathology. 2026;46(2). doi:10.1111/neup.70056
BibTeX
@article{Behera2026,
author = {Behera, Minakshi M and Purkait, Suvendu and Ghosh, Amit and Sable, Mukund N and Sahu, Rabi Narayan and Chhabra, Gaurav},
title = {Transferrin Receptor 1 Overexpression Drives Proliferation and Ferroptosis Sensitivity in Glioblastoma: A Potential Therapeutic Vulnerability},
journal = {Neuropathology},
year = {2026},
volume = {46},
number = {2},
doi = {10.1111/neup.70056}
}
EUVIMED